Quebec is considering a significant regulatory change that would require Benadryl and other medications containing diphenhydramine to be sold only behind pharmacy counters, according to a report by Laurence Brisson Dubreuil. The proposed measure aims to address growing concerns over the misuse of the popular allergy drug, which can cause serious side effects when taken in large doses.
Why the Change Is Being Considered
Health officials in Quebec have raised alarms about the potential for abuse of diphenhydramine, an antihistamine commonly used in allergy relief products like Benadryl. The drug is known to have sedative effects, and when consumed in high quantities, it can lead to severe health risks, including hallucinations, seizures, and even death. The move to restrict access behind pharmacy counters would allow pharmacists to monitor sales and provide guidance on proper use.
According to sources familiar with the discussions, the Quebec government is responding to an increase in reports of misuse, particularly among young people. A stock photo of a 36-caplet package of Benadryl allergy medication accompanied the original report, highlighting the widespread availability of the product.
Potential Impact on Consumers
If implemented, the policy would require consumers to speak directly with a pharmacist before purchasing Benadryl. This could help reduce accidental overdoses and discourage intentional misuse. However, it may also inconvenience those who rely on the medication for legitimate allergy relief, as they would no longer be able to grab it off the shelf.
The proposal is part of a broader trend in Canada to tighten controls over over-the-counter medications that have abuse potential. Similar restrictions already exist for other drugs, such as codeine-containing products, which are kept behind pharmacy counters in many provinces.
Next Steps in the Regulatory Process
The Quebec government has not yet announced a timeline for a decision. The measure would likely require consultation with pharmacists, healthcare professionals, and the public before being finalized. If approved, it could take effect in 2027 or later, according to the report.
“This is about protecting public health,” a government official said, speaking on condition of anonymity. “We need to ensure that medications like Benadryl are used safely and responsibly.”
Broader Context of Drug Regulation
The move comes amid heightened scrutiny of over-the-counter drug safety across Canada. In recent years, Health Canada has reviewed the risks of diphenhydramine, particularly for children and older adults. The agency has previously warned against using the drug as a sleep aid due to its potential for side effects.
Quebec’s consideration of this policy aligns with actions taken in other jurisdictions. Some U.S. states have also explored restricting diphenhydramine sales, though no federal mandate exists.
The final decision will depend on further analysis and stakeholder input, but the proposal signals a significant shift in how common allergy medications may be regulated in Quebec.
